Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)

BACKGROUND: We assessed the efficacy and safety of mirabegron, a β(3)-adrenoceptor agonist, in older adults (≥ 80 years old) with overactive bladder (OAB). METHODS: OAB patients aged ≥ 80 years were enrolled in this prospective, single-arm observational study. OAB was diagnosed based on the OAB symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagomi, Hiroshi, Mitsui, Takahiko, Shimura, Hiroshi, Ihara, Tatsuya, Kira, Satoru, Sawada, Norifumi, Takeda, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939141/
https://www.ncbi.nlm.nih.gov/pubmed/35313873
http://dx.doi.org/10.1186/s12894-022-00989-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939141/
https://www.ncbi.nlm.nih.gov/pubmed/35313873
http://dx.doi.org/10.1186/s12894-022-00989-7

Ejemplares similares